Korea Arlico Pharm Co.,Ltd.

KOSDAQ:A260660 Stock Report

Market Cap: ₩52.4b

Korea Arlico PharmLtd Valuation

Is A260660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A260660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A260660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A260660's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A260660?

Key metric: As A260660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A260660. This is calculated by dividing A260660's market cap by their current revenue.
What is A260660's PS Ratio?
PS Ratio0.3x
Sales₩178.83b
Market Cap₩52.42b

Price to Sales Ratio vs Peers

How does A260660's PS Ratio compare to its peers?

The above table shows the PS ratio for A260660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
A014570 Korean Drug
0.7xn/a₩48.8b
A017180 MYUNGMOON PharmLtd
0.4xn/a₩63.2b
A000220 Yuyu Pharma
0.5xn/a₩68.0b
A200780 BCWORLD PHARM
0.5xn/a₩38.6b
A260660 Korea Arlico PharmLtd
0.3xn/a₩52.4b

Price-To-Sales vs Peers: A260660 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does A260660's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$158.67m
A002620 Jeil Pharma Holdings
0.2xn/aUS$92.36m
A000230 Ildong Holdings
0.1xn/aUS$57.08m
No more companies available in this PS range
A260660 0.3xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A260660 is good value based on its Price-To-Sales Ratio (0.3x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A260660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A260660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A260660's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

7D

-0.7%

1Y

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

7D

-4.8%

1Y

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

7D

2.1%

1Y

-41.2%